Experts unveil new recommendations after analysis of Covid-19 mortality data in pregnant women Photo: Bigstock
In a press release published on Monday (5), the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) recommends the resumption of vaccination of all pregnant women in the country against Covid-19. They now include both pregnant women with co-morbidities and those without risk factors for infection with the novel coronavirus.
The entity recalls that the measure is in accordance with the National Vaccination Plan (PNI) and that the vaccination must be carried out with vaccines available in Brazil that do not contain a viral vector. In this case, Coronavac, produced by the Sinovac laboratory and the Instituto Butantan, and Comirnaty, developed by Pfizer / BioNTech.
Follow Semper Familia on Instagram!
“Febrasgo understands that the use of covid-19 vaccines in pregnant women with and without comorbidities or risk factors should occur regardless of the medical indication, and that it is not necessary, if the pregnant woman or in postpartum wishes, to present a prenatal birth. or registration of the birth of the child, ”said the entity in the statement published on the website.
Both pregnant women included in the priority groups and those without comorbidity who have not yet been vaccinated should receive the vaccinations according to the PNI schedule of each municipality.
Currently, in Brazil, the inclusion of pregnant women without comorbidities in the vaccination against Covid-19 varies by city. Curitiba, for example, returned to vaccinate this group in early June. In May, the Department of Health recommended the suspension of vaccination of pregnant women without comorbidity, following Anvisa’s guidelines for the PNI to maintain the recommendations provided in the AstraZeneca / Oxford / Fiocruz vaccine package insert.
Last Friday (2), Anvisa proposed restrictions on the use of vaccines containing viral vectors for pregnant women – including not only AstraZeneca’s vaccine, but Janssen’s as well.
For pregnant and post-partum women who received the first dose of the AstraZeneca-Oxford / Fiocruz vaccine in early May, the organization offers two alternatives:
Either they wait until the end of the gestation and puerperium period (up to 45 days after childbirth) and receive the second dose of the same vaccine; Either they receive the second dose of the vaccine from Pfizer / BioNTech or Coronavac – in places where the vaccine is not available.
“Pregnant women and postpartum women (including those without additional risk factors) who have already received the first dose of another COVID-19 vaccine that does not contain a viral vector (such as Sinovac / Butantan or Pfizer) must end the diet with the same vaccine at the usual intervals “, supplement the specialists via Febrasgo.
Increased risk of Covid-19 in pregnant women
According to Febrasgo, the shift in focus was made after analyzing morbidity, mortality and risk of death data from Severe Acute Respiratory Syndrome (SRAG) / Covid-19 in pregnant and postpartum women.
“(…) it was considered that the risk of worsening and death in pregnant and postpartum women after infection with SARS-CoV-2 showed a significant increase during weeks 17 to 23 2021. 19 in pregnant women without comorbidities and / or risk with inactivated vaccines (Coronavac) and mRNA (Pfizer), without the need for an indication or a medical report. “
The entity recalls, however, that the recommendations may be revised at any time, depending on new scientific evidence.